Business Wire

PANASONIC

Share
Independent Test Results confirm an inhibitory effect on the novel coronavirus (SARS-CoV-2) by Panasonic’s air conditioner with nanoe™ X

Panasonic Corporation today announced that, in a European first, Texcell*1 , a global contract research organisation, has certified the inhibitory effect on the novel coronavirus (SARS-CoV-2) by an air conditioner with nanoe™ X. Texcell verified 91.4% of the inhibitory effect on the novel coronavirus in a space of 6.7m3 over 8 hours.

nanoe™ X is a technology that collects invisible moisture in the air and applies a high voltage to it to produce “hydroxyl radicals contained in water”. Hydroxyl radicals inhibit the growth of pollutants such as certain bacteria and viruses. They are characterised by being strongly oxidative and highly reactive, hence a short life span. Contained in tiny water particles, nanoe™ X has a long lifespan and can spread over long distances. It has an inhibitory effect on both airborne and adhered substances.

In September 2020, and in collaboration with Texcell*1 , Panasonic verified the inhibitory effect of the nanoe™ X technology with the benefits of hydroxyl radicals on the novel coronavirus in a small test space of 45L using nanoe™ X generator. For further investigation, Panasonic challenged to test using an air conditioner with nanoe™ X in a larger test space. Even in these difficult circumstances, Texcell has now certified that the nanoe™ X does have a 91.4% inhibitory effect on the novel coronavirus in the actual space of 6.7m3 over 8 hours using the air conditioner with nanoe™ X. This testing was carried out in a closed laboratory environment and was not designed to assess its efficacy in uncontrolled living spaces.

Panasonic has been conducting research on nanoe™ Technology over the past 20 years since 1997 and has verified its effectiveness in a variety of areas, including inhibiting pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*2 .

Panasonic will continue to pursue the potential of nanoe™ X technology to address possible risks associated with air pollution such as new pathogenic microorganisms, to create healthy environments for people around the world.

For reference:
Testing the inhibitory effect of air conditioner with nanoe™ X on the novel coronavirus (SARS-CoV-2) in a space of 6.7m3 .  

Overview
A comparative verification was conducted in a space of 6.7m3 containing the novel coronavirus. (SARS-CoV-2)

Results
Over 91% of novel coronavirus (SARS-CoV-2) activity was inhibited within 8 hours.

Note: This verification was designed to generate basic research data on the effects of nanoe™ X on the novel coronavirus in laboratory conditions different from those found in living spaces.

Methodology and data
Organisation :Texcell (France)
Subject :Novel coronavirus (SARS-CoV-2)
Device :Air conditioner with nanoe™ X (Etherea model CS-Z25VKEW)
Method:

  • The Etherea air conditioner with nanoe™ X is installed in a space of 6.7m3 .
  • Gauze saturated with SARS-CoV-2 virus solution was exposed to an air conditioner with nanoe™ X from a distance of 0.7m in a 6.7m3 room for 24 hours.
  • The virus infectious titre was measured and used to calculate the inhibition rate.

Test result

Test subject

Inhibition rate

Capacity

Hours

SARS-CoV-2

42.4%

6.7 m3

4 hours

SARS-CoV-2

91.4%

6.7 m3

8 hours

SARS-CoV-2

99.7%

6.7m3

24 hours

 

Notes:
*1: Texcell is a global contract research organisation that specialises in viral testings, viral clearance, immunoprofiling and R&D or GMP cell banking, for your R&D, GClP, GLP and GMP projects.

With more than 30 years of experience and roots within the Pasteur Institute in Paris, Texcell has a long recognized expertise in viral testing with a broad range of protocols for the detection of adventitious agents.

Texcell is the first spin-off of the Pasteur institute of Paris created in 1997.

*2: Main releases on verification cases
- May 12, 2009:Positive effects of charged water particles on viruses, bacteria, and agricultural chemicals have been verified.
- October 20, 2009: The new influenza virus inhibition effect of charged water particles has been verified.
- February 20, 2012:Suppression effect of charged water particles on pet-related allergens, bacteria, fungi, and viruses have been verified.
- January 16, 2014:Nano-sized electrostatic atomised water particles effectively breaks down PM2.5 components and inhibits growth of fungi attached to Yellow Sand.

About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quectel Launches SP895BD-AP Smart Module, Powering the Next Generation of Intelligent IoT Applications5.1.2026 15:33:00 CET | Press release

Quectel Wireless Solutions, an end-to-end global IoT solutions provider, announced the official launch of its new-generation flagship smart module, the SP895BD-AP. Powered by the Qualcomm Dragonwing™ Q-8750 processor, the SP895BD-AP module boasts enhanced graphics processing capabilities, superior visual imaging effects, and advanced edge computing performance, meeting the requirements of high-end devices such as video conferencing systems, ultra-high-definition (UHD) displays, image synthesis equipment, computing power boards, smart retail terminals and smart home appliances. The SP895BD-AP redefines performance boundaries with its advanced hardware architecture. Powered by the Dragonwing Q-8750 processor built on a 3nm process, it features an 8-core high-performance Oryon™ CPU with a maximum frequency of 2×4.32 GHz + 6×3.53 GHz. Compared with the previous-generation (Series 8) chips, it achieves a 45% improvement in CPU performance and a 44% optimization in energy efficiency. This en

The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services5.1.2026 15:00:00 CET | Press release

The acquisition strengthens DIETL’s fine art logistics operations through expanded access to specialized storage, handling and customs services. The Rock-It Company announced today that DIETL has acquired multiple fine art logistics specialists, strengthening its infrastructure and expanding access to specialized services across key U.S. art markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105175923/en/ The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services The acquired companies include Delaware Freeport, Delaware National Art Company, Techno Export, and Registrar Technologies. Together, these businesses add depth across fine art storage, handling, packing, crating, installation support, customs brokerage, and technology-enabled logistics services, complementing DIETL’s existing operations. Delaware Freeport, a provider of high-security

TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release

Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye